J. Safra Sarasin Holding AG Sells 134 Shares of DaVita Inc. (NYSE:DVA)

J. Safra Sarasin Holding AG lessened its stake in DaVita Inc. (NYSE:DVA) by 0.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,200 shares of the company’s stock after selling 134 shares during the period. J. Safra Sarasin Holding AG’s holdings in DaVita were worth $4,217,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in DVA. Epoch Investment Partners Inc. bought a new stake in DaVita during the fourth quarter valued at $55,100,000. Invesco Ltd. lifted its holdings in shares of DaVita by 20.9% in the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company’s stock worth $237,716,000 after purchasing an additional 275,284 shares in the last quarter. Amundi increased its position in shares of DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after acquiring an additional 240,126 shares in the last quarter. Bridgewater Associates LP increased its holdings in DaVita by 298.4% during the 4th quarter. Bridgewater Associates LP now owns 239,970 shares of the company’s stock worth $35,888,000 after purchasing an additional 179,744 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ raised its position in DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock valued at $24,301,000 after buying an additional 116,758 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Performance

NYSE:DVA opened at $133.73 on Tuesday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 1-year low of $128.69 and a 1-year high of $179.60. The business has a 50 day moving average of $148.36 and a 200 day moving average of $155.79. The company has a market capitalization of $10.70 billion, a price-to-earnings ratio of 12.45, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, sell-side analysts predict that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Barclays lifted their target price on shares of DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Thursday, April 10th. Finally, Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.